Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19

The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients. OLUMIANT is a once-daily, oral JAK inhibitor developed by Incyte (NASDAQ:INCY) and licensed to Eli Lilly and Company (NYSE:LLY). 

The regulatory approval is supported by results from Phase 3 studies of ACTT@ and COV-BARRIER. No new safety signals potentially related to the use of OLUMIANT were identified in the studies.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.